MIRM:NSD-Mirum Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 41.12

Change

-0.01 (-0.02)%

Market Cap

N/A

Volume

0.31M

Analyst Target

USD 48.71
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing MIRM

BBP Virtus LifeSci Biotech Pr.. 2.31 % 0.79 %

+0.30 (+0.63%)

USD 0.02B
IWC iShares Micro-Cap ETF 0.00 % 0.60 %

+0.77 (+0.63%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.30% 78% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.30% 78% C+ 88% B+
Trailing 12 Months  
Capital Gain 25.18% 71% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.18% 70% C- 75% C
Trailing 5 Years  
Capital Gain 310.38% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.38% 93% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 25.04% 74% C 81% B-
Dividend Return 25.04% 74% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.76% 69% C- 44% F
Risk Adjusted Return 59.97% 97% N/A 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector